PMID- 23098495
OWN - NLM
STAT- MEDLINE
DCOM- 20130418
LR  - 20210816
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 13
IP  - 8
DP  - 2012
TI  - Variants on ESR1 and their association with prostate cancer risk: a 
      meta-analysis.
PG  - 3931-6
AB  - BACKGROUND: Epidemiological studies evaluating the association of two variants 
      rs9340799 and rs2234693 on estrogen receptor 1 (ESR1) with prostate risk have 
      generated inconsistent results. METHODS: A meta-analysis was here conducted to 
      systematically evaluate the relationship of these two variants with prostate 
      cancer susceptibility. RESULTS: For rs9340799, heterozygosity of T/C carriers 
      showed a significant increased prostate cancer risk with a pooled odds ratio (OR) 
      of 1.34 (95% CI = 1.06-1.69) while homozygote C/C carriers showed an increased 
      but not statistically significant association with prostate cancer risk (pooled 
      OR = 1.29, 95% CI = 0.94-1.79). Compared to the homozygous TT carriers, the 
      allele C carriers showed a 31% increased risk for prostate cancer (pooled OR = 
      1.31, 95% CI = 1.06-1.63). No significant association between the rs2234693 and 
      prostate cancer risk was found with the pooled OR of 1.15 (95% CI = 0.97-1.39, 
      T/C and C/C vs. T/T) under the dominant genetic model. Compared to the homozygote 
      T/T carriers, the heterozygous T/C carriers did not show any significantly 
      different risk of prostate cancer (pooled OR = 1.13, 95% CI = 0.94-1.36) and the 
      homozygous C/C carriers also did not show a significant change for prostate 
      cancer risk compared to the wide-type T/T carriers (pooled OR = 1.26, 95% CI = 
      0.98-1.62). CONCLUSIONS: These data suggested that variant rs9340799, but not 
      rs2234693, on ESR1 confers an elevated risk of prostate cancer.
FAU - Ding, Xiang
AU  - Ding X
AD  - Department of Urology, First Affiliated Hospital of Soochow University, Suzhou, 
      China.
FAU - Cui, Feng-Mei
AU  - Cui FM
FAU - Xu, Song-Tao
AU  - Xu ST
FAU - Pu, Jin-Xian
AU  - Pu JX
FAU - Huang, Yu-Hua
AU  - Huang YH
FAU - Zhang, Jiang-Lei
AU  - Zhang JL
FAU - Wei, Xue-Dong
AU  - Wei XD
FAU - Hou, Jian-Quan
AU  - Hou JQ
FAU - Yan, Chun-Yin
AU  - Yan CY
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (ESR1 protein, human)
RN  - 0 (Estrogen Receptor alpha)
SB  - IM
MH  - Case-Control Studies
MH  - Estrogen Receptor alpha/*genetics
MH  - *Genetic Predisposition to Disease
MH  - Humans
MH  - Male
MH  - Polymorphism, Genetic/*genetics
MH  - Prostatic Neoplasms/*etiology
MH  - Risk Factors
EDAT- 2012/10/27 06:00
MHDA- 2013/04/20 06:00
CRDT- 2012/10/27 06:00
PHST- 2012/10/27 06:00 [entrez]
PHST- 2012/10/27 06:00 [pubmed]
PHST- 2013/04/20 06:00 [medline]
AID - 10.7314/apjcp.2012.13.8.3931 [doi]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2012;13(8):3931-6. doi: 10.7314/apjcp.2012.13.8.3931.